Press Releases
ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development
ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease
ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research
ROME Therapeutics Appoints Industry Veteran Jeff Hatfield as Chair of Board of Directors
In the news
New frontier in biology: harnessing the power of the repeatome with Dennis Zaller | Biotech2050 podcast
Publications and presentations
ROME Therapeutics company presentation | 41st J.P. Morgan Healthcare Conference
LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses | American College of Rheumatology Convergence 2022